Articles tagged "Kidney transplantation"

2015 American Transplant Congress
Changes in Immunophenotypes After Conversion from Calcineurin Inhibitors to mTOR Inhibitors in Renal Transplant Recipients
A. Yildiz,^1,4 M. Cavusoğlu,¹ S. Adin,² Y. çaliskan,¹ A. Ozkok,¹ H. Tasçi,³ G. Deniz,² M. Sariyar.³
¹Internal Medicine, Nephrology, Istanbul School of Medicine, Istanbul, Turkey; ²Immunology, Experimental Medicine and Research Center, Istanbul, Turkey; ³General Surgery, Medicana Organ Transplant Center, Istanbul, Turkey.
Chronic toxicity of calcineurin inhibitors (CNI) is one of the major causes of chronic allograft loss. Conversion from CNI to mTOR ((mammalian target of rapamycin)…
2015 American Transplant Congress
OX40 Gene: A Potential Target for the Care of Chronic T-Cell Mediated Rejection (TCMR)
F. Schena,¹ C. Curci,¹ F. Sallustio,¹ M. Trpevski,¹ G. De Palma,¹ M. Fiorentino,² M. Rossini,² M. Quaglia,³ E. Bozzola,³ S. Zanini,⁴ L. Furian,⁴ A. Toscano,⁵ E. Gallo,⁶ L. Gesualdo,² P. Stratta,³ P. Rigotti,⁴ F. Citterio,⁵ L. Biancone.⁶
¹C.A.R.S.O. Consortium, Valenzano, Italy; ²University of Bari, Bari, Italy; ³A.O.U. Maggiore della Carità, Novara, Italy; ⁴University of Padova, Padua, Italy; ⁵Cattolica Sacro Cuore University, Rome, Italy; ⁶University of Torino, Turine, Italy.
Introduction:TCMR is characterized by the reduction of vessel lumen with marked intimal thickening, fibrous hyperplasia and a strong component of leukocyte infiltrate. Aim of our…
2015 American Transplant Congress
Kidney Transplant Telehealh Clinic Improves Access to Long-Term Follow-Up and Decreases Costs: The Experience of the Iowa City VA Transplant Program
R. Kalil,^1,2 C. Thomas,^1,2 D. Katz.^1,2
¹Univesity of Iowa, Iowa City; ²Iowa City VAMC, Iowa City.
Kidney transplant (KT) recipients living in areas distant from transplant centers face more challenges in maintaining adequate follow-up due to long travel distances, greater costs,…
2015 American Transplant Congress
The Impact of FcγRIIA, FcγRIIIA and C1QA Genes Polymorphism On Infectious Complications Following Renal Transplantation
L. Das, Y. Tanaka, S. Verma, S. Shimizu, K. Ide, H. Ohdan.
Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
AIM- Infectious complication is the leading cause of graft and patient loss after renal transplantation (RT). Under immunosuppressive condition when acquired immunity is suppressed, components…
2015 American Transplant Congress
Once Daily Dosing Is as Effective as Twice Daily Dosing of Immediate Release Tacrolimus
L. Bowman,¹ T. Horwedel,¹ J. Hagopian,¹ B. Bone,² H. Wijeweera,² D. Brennan.²
¹Barnes-Jewish Hospital, St. Louis; ²Washington University School of Medicine, St. Louis.
Purpose: Extended release (ER) tacrolimus (tac) has been available as Advagraf® for many years and as Astagraf XL® in the US since 2013. Immediate release…
2015 American Transplant Congress
Safety and Efficacy of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients
Y. Watarai,¹ M. Okada,¹ K. Futamura,¹ K. Ito,¹ T. Yamamoto,¹ M. Tsujita,¹ T. Hiramitsu,¹ N. Goto,¹ S. Narumi,¹ T. Kobayashi.²
¹Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan; ²Applied Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Recently, once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well evaluated. We have validated low dose…
2015 American Transplant Congress
Medication Adherence in Adolescents With Kidney Transplant and Chronic Kidney Disease: Patient/Caregiver Report Vs. Provider Perception
C. Pruette,¹ T. Brady,¹ S. Mendley,² B. Fivush,¹ S. Tuchman,³ A. Green,¹ M. Eakin,¹ K. Riekert.¹
¹Johns Hopkins University School of Medicine, Baltimore, MD; ²University of Maryland School of Medicine, Baltimore, MD; ³Children's National Medical Center, Washington, DC.
Background: Medication adherence in adolescent kidney transplant (KT) recipients is poor, with non-adherence (NA) ranging from 5-71%, and NA is associated with poor graft survival.…
2015 American Transplant Congress
Clinical Course of Pre-Existing Monoclonal Gammopathies Following Kidney Transplant
C. Johnson.
Nephrology, University of Washington, Seattle, WA.
INTRODUCTIONThe progression of monoclonal gammopathies following kidney transplant is not well described. Previous single-center retrospective data suggested that the course for a monoclonal gammopathy of…
2015 American Transplant Congress
HLA Broad Antigen and Eplet Mismatches in Determining the Risk of Acute Rejection After Kidney Transplantation
H. Do Nguyen,¹ W. Lim,^1,2 J. Chapman,³ J. Craig,^3,4 G. Wong.^3,4
¹School of Medicine and Pharmacology, University of Western Australia, Crawley, Western Australia, Australia; ²Renal Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia; ³Nephrology, The Children's Hospital at Westmead, Sydney, New South Wales, Australia; ⁴School of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Aim: To determine the clinical relevance of HLA-ABDR broad antigen and eplet matching for predicting acute rejection after kidney transplantation.Background: HLAMatchmaker determines structurally HLA compatibility…
2015 American Transplant Congress
Donor-Specific Alloantibody After Positive Crossmatch Kidney Transplantation With Eculizumab (EC): Correlation With Transplant Glomerulopathy and Graft Failure
C. Schinstock,¹ F. Cosio,¹ L. Cornell,¹ M. Gandhi,¹ M. Everly,² M. Stegall.¹
¹Mayo Clinic, Rochester, MN; ²Paul Terasaki Foundation, Los Angeles, CA.
Introduction. EC (C5 blockade) reduces the incidence of early clinical acute antibody mediated rejection (AMR) after +XMKTx, but does not prevent chronic AMR. We examined…